We are excited to announce that recent research on N-myristoyltransferase inhibition (NMTi) will be presented at two recent European conferences, the European Hematology Association’s EHA2023 Hybrid Congress June 8-11 and the European Association for Cancer Research (EACR) June 12-15. These results expand the understanding of how NMT inhibition selectively kills cancer cells.
Further data on identifying cancer cells likely to respond to NMT inhibition therapy will also be included in the EACR presentation June 12-15 where details of a gene expression signature set, MISS-91 (Myristoylation Inhibitors Sensitivity Signature), will be described. MISS-91 predicts multiple cancers that are sensitive to PCLX-001, a first-in-class small molecule NMT inhibitor, including both hematologic and solid tumors, at concentrations at which normal tissues would be insensitive.
Read the full press release here.